日水製薬(株)の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証PRM | 医薬品 | 4550/E00971 | Nissui Pharmaceutical Co., Ltd |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2012/01/20 | 日証協 | 3,500株 | +16.67% | 800株 | -52.94% | 55,835株 | -1.76% | 1,400株 | -46.15% |
| 2012/01/13 | 日証協 | 3,000株 | +7.14% | 1,700株 | +70% | 56,835株 | -2.07% | 2,600株 | +420% |
| 2012/01/06 | 日証協 | 2,800株 | 0% | 1,000株 | -50% | 58,035株 | +2.27% | 500株 | -77.28% |
| 2011/12/30 | 日証協 | 2,800株 | +3.7% | 2,000株 | +17.65% | 56,749株 | +1.43% | 2,201株 | -67.18% |
| 2011/12/22 | 日証協 | 2,700株 | +3.85% | 1,700株 | -58.54% | 55,949株 | +1.45% | 6,707株 | +4.8% |
| 2011/12/16 | 日証協 | 2,600株 | 0% | 4,100株 | +36.67% | 55,148株 | +3.79% | 6,400株 | +165.01% |
| 2011/12/09 | 日証協 | 2,600株 | +100% | 3,000株 | +57.89% | 53,133株 | -3.3% | 2,415株 | +20.75% |
| 2011/12/02 | 日証協 | 1,300株 | -18.75% | 1,900株 | +90% | 54,948株 | +2.42% | 2,000株 | -4.76% |
| 2011/11/25 | 日証協 | 1,600株 | +220% | 1,000株 | +66.67% | 53,648株 | +2.29% | 2,100株 | -80.37% |
| 2011/11/18 | 日証協 | 500株 | -16.67% | 600株 | -40% | 52,448株 | +1.75% | 10,700株 | -26.21% |
| 2011/11/11 | 日証協 | 600株 | -53.85% | 1,000株 | +11.11% | 51,548株 | -2.83% | 14,500株 | +74.7% |
| 2011/11/04 | 日証協 | 1,300株 | -7.34% | 900株 | +197.03% | 53,049株 | +1.34% | 8,300株 | -27.21% |
| 2011/10/28 | 日証協 | 1,403株 | -17.47% | 303株 | -85.57% | 52,349株 | 0% | 11,403株 | +54.09% |
| 2011/10/21 | 日証協 | 1,700株 | +13.33% | 2,100株 | +950% | 52,349株 | +1.36% | 7,400株 | +37.04% |
| 2011/10/14 | 日証協 | 1,500株 | -51.61% | 200株 | -94.59% | 51,649株 | -0.19% | 5,400株 | -65.61% |
| 2011/10/07 | 日証協 | 3,100株 | -13.89% | 3,700株 | -40.32% | 51,749株 | +48.15% | 15,702株 | +22.51% |
| 2011/09/30 | 日証協 | 3,600株 | -20% | 6,200株 | +675% | 34,930株 | -38.88% | 12,817株 | -32.19% |
| 2011/09/22 | 日証協 | 4,500株 | +50% | 800株 | -83.67% | 57,148株 | +23.3% | 18,900株 | +11.83% |
| 2011/09/16 | 日証協 | 3,000株 | +100% | 4,900株 | +113.04% | 46,348株 | +0.43% | 16,900株 | -5.06% |
※株式分割は考慮していませんのでご注意ください。